Clinical trials: Allogeneic Disease
Tourette Syndrome
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for Tourette Syndrome
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Tourette Syndrome
- Trial name
- NCT05158439
- Testing
- Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
cGVHD
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
The study plan aims to include patients who have been diagnosed with steroid-refractory chronic GVHD in the liver following allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT06364319
- Testing
- anti-CD25 rhMAb, Prednisone, Ruxolitinib
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Acute Graft Versus Host Disease
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while…
- Trial name
- NCT00032773
- Testing
- pentostatin for injection
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Astex Pharmaceuticals, Inc.
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Phase I Study of Milatuzumab for Graft Versus Host Disease
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT01663766
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
Patients Undergoing Allogeneic Stem Cell Transplantation
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
In patients after allogeneic stem cell transplantation reactivation of latent herpesviruses such as Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) is a frequent and life threatening complication requiring antiviral treatment.
- Trial name
- NCT02227641
- Testing
- CMV/EBV specific T-cell
- Where
- 6 sites in Germany
- Volunteers
- 50 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
- Conditions
- Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05795595
- Testing
- CTX131
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- CRISPR Therapeutics AG
AML (Acute Myelogenous Leukemia), Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission
This is a single-center, prospective, exploratory clinical study. It plans to enroll 30 adult patients with acute myeloid leukemia (AML) who have achieved first complete remission (CR1) after induction therapy and meet the…
- Trial name
- NCT07644481
- Testing
- CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
This phase I trial studies how well the combination of magrolimab works with azacitidine after a donor stem cell transplant (allogeneic hematopoietic cell transplantation) in treating patients with high-risk acute myeloid…
- Trial name
- NCT05823480
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection
- Sponsor
- City of Hope Medical Center
Alzheimer Disease
the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease
Evaluate the Safety and Efficacy of Exosomes Derived from Allogenic Adipose Mesenchymal Stem Cells（MSCs-Exos）in Subjects with Alzheimer's disease.
- Trial name
- NCT04388982
- Testing
- low dosage MSCs-Exos administrated for nasal drip, mild dosage MSCs-Exos administrated for nasal drip, high dosage MSCs-Exos administrated for nasal drip
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Ruijin Hospital
Steroid-refractory Bronchiolitis Obliterans
A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT
Improvement of quality of life in patients with BO and establishment of a new third line therapy
- Trial name
- IFN_BOSZT_01 (NCT01639261)
- Testing
- Interferon gamma 1b
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital Regensburg
Pancreatic Cancer
Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer
This is an open label, phase II trial study of adjuvant GVAX pancreas vaccine in patients with pancreatic cancer.
- Trial name
- NCT00389610
- Testing
- GVAX pancreas vaccine
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non Hodgkin Lymphoma, Hodgkin Lymphoma
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
The study hypotheses is that the introduction of dose escalated thiotepa, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with…
- Conditions
- Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT02507479
- Testing
- Thiotepa
- Where
- 2 sites in Israel
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
In this study the investigators investigate a cell therapy strategy that could harness allogeneic effectors that can potentially mediate anti-lymphoma effect.
- Trial name
- NCT01181258
- Testing
- Rituximab, Interleukin-2, Natural killer cells
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metastatic Colorectal Cancer
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
This study will be looking at whether CY/GVAX in combination with SGI-110 is effective (recruits CD45RO+ T cells to the tumor which may be a marker of anti-tumor activity) and safe in patients with metastatic colon or rectum…
- Trial name
- NCT01966289
- Testing
- CY, GVAX, SGI-110
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Type 1 Diabetes Mellitus
Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus
In this prospective, dual-center, open trial, patients with recent onset type 1 diabetes will receive one dose of allogenic Adipose tissue-derived stromal/stem cells (1x106 cells/kg) and oral cholecalciferol 2000UI/day for 24…
- Trial name
- NCT03920397
- Testing
- Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Trachea Diseases, Airway Remodeling
Feasibility of Tracheobronchial Defect Reconstruction Using Allogenic Aortic Patch
The investigators investigate the feasibility and safety of using cryopreserved aortic patches for tracheal or bronchial defect repair.
- Conditions
- Trachea Diseases, Airway Remodeling, Reconstruction Surgery
- Trial name
- NCT06935110
- Testing
- Cryopreserved aortic patch
- Where
- 2 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital
Alzheimer Disease
Alzheimer's Disease Stem Cells Multiple Infusions
The purpose of this research study is to test the safety, possible side effects, and possible effectiveness of mesenchymal stem cell infusions when given to people with a diagnosis of mild to moderate Alzheimer's disease.
- Trial name
- NCT04040348
- Testing
- Approximately 100 million cells allogeneic hMSC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Bernard (Barry) Baumel
Acute Myeloid Leukemia or Myelodysplastic Syndromes
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
A multi-center, open label, Phase II clinical trial to assess the safety and efficacy of APR-246 in combination with azacitidine as maintenance therapy after allogeneic HSCT (hematopoietic stem cell transplant) for patients with…
- Trial name
- NCT03931291
- Testing
- APR-246
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- Aprea Therapeutics
Vaccine Response Impaired, Respiratory Syncytial Virus Infections
RSV Vaccine in Transplant Recipients
Adjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied.
- Conditions
- Vaccine Response Impaired, Respiratory Syncytial Virus Infections, Immune Suppression
- Trial name
- RSVax (NCT06593210)
- Testing
- Adjuvant, non-live RSV vaccine
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University Health Network, Toronto
Non-hodgkin Lymphoma
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double genes deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL)…
- Trial name
- NCT06323525
- Testing
- TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T), Fludarabine, Cyclophosphamide
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.